Business Monitor International


New Zealand Pharmaceuticals & Healthcare Report

Published 27 August 2014

  • 88 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
New Zealand Pharmaceuticals & Healthcare Report

BMI View: L imited pharmaceutical reimbursement in New Zealand will remain a key issue for innovative pharmaceutical firms as the country seeks to maintain tight control over pharmaceutical spending. Between 2013 and 2018, BMI forecasts that pharmaceutical sales in New Zealand will grow at a local compound annual growth rate (CAGR) of 2.7% (-0.5% in US dollar terms).

Headline Expenditure Forecasts

  • Pharmaceuticals : NZD1.42bn (USD1.17bn) in 2013 to NZD1.46bn (USD1.10bn) in 2014; +2.8% in local currency terms.

  • Healthcare: NZD21.75bn (USD17.83bn) in 2013 to NZD22.33bn (USD18.36bn) in 2014; +2.7% in local currency terms.

Risk/Reward Rating: New Zealand's score of 53.6 out of 100 is boosted by its stable economic and political environments and well developed regulatory processes. However, it has a small and relatively low-growth potential market, and a low industry risks score because of its regulatory processes. The country is ranked ninth out of the 19 markets in the Asia Pacific RRR matrix.

Key Trends & Developments

  • In June 2014, the demand for measles vaccine increased by 40% in New Zealand in the wake of a fast-spreading outbreak of the disease in the Auckland and Waikato regions.

  • In June 2014, PHARMAC announced changes to funding access criteria for a number of vaccines. The changes in criteria come after consideration of feedback from consultations on previous changes to the Immunisation Schedule posted on PHARMAC's webpage on December 19 2013 and November 6 2013 and from recommendations from the Immunisation Subcommittee, which met in February 2014.

  • From July 1, New Zealand citizens will get extensive access to new and existing vaccines. The Immunisation Handbook 2014, published by the Health Ministry and launched by the Associate Minister of Health, Hon Jo Goodhew, details the access to funded vaccines for varicella, rotavirus and others vaccines meant for at-risk groups.

  • In May 2014, New Zealand-based retirement village operator Ryman...

Table of Contents

BMI Industry View
7
SWOT
9
Political
10
Economic
11
Business Environment
13
Industry Forecast
15
Pharmaceutical Market Forecast
15
Table: Pharmaceutical Sales, Historical Data And Forecasts (New Zealand 2010-2018)
16
Healthcare Market Forecast
17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2010-2018)
18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2010-2018)
18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2010-2018)
18
Prescription Drug Market Forecast
19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (New Zealand 2010-2018)
20
Patented Drug Market Forecast
21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (New Zealand 2010-2018)
22
Generic Drug Market Forecast
23
Table: Generics Drug Market Indicators, Historical Data And Forecasts (New Zealand 2010-2018)
24
OTC Medicine Market Forecast
25
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (New Zealand 2010-2018)
26
Pharmaceutical Trade Forecast
27
Table: Pharmaceutical Trade Data And Forecast (New Zealand 2012-2018)
28
Table: Pharmaceutical Trade Data And Forecasts local currency (New Zealand 2012-2018)
28
Other Healthcare Data
29
Key Risks To BMI's Forecast Scenario
30
Macroeconomic Forecasts
31
Economic Analysis
31
Expectations For Interest Rate Hikes To Weigh On Consumption Growth
33
External And Domestic Uncertainties To Cap Growth In Business Spending
34
Risks To Outlook
35
Industry Risk Reward Ratings
36
Asia Risk/Reward Ratings
36
New Zealand Risk/Reward Ratings
42
Rewards
42
Risks
42
Market Overview
44
Industry Trends And Developments
45
Epidemiology
45
Healthcare Sector
47
Infrastructure
49
Table: Regional Ranking of Projected Physicians, 2017
51
Table: Projected Physicians, 2012-2017
52
Table: Active Medical Practitioners, 2005-2010
52
Distribution Channels
53
Table: Pharmacybrands Stores by Company & Region, 2010
55
Research and Development (R&D)
55
Clinical Trials Sector
56
Regulatory Development
58
Regulatory Regime
58
Intellectual Property Regime
58
Pricing & Reimbursement
59
Table: Leading Therapeutic Groups By PHARMAC Expenditure (NZDmn), 2005-2010
63
Table: Top 20 Medicines By Ex-Manufacturer Cost To PHARMAC In The Year Ending June 2010 (NZDmn)
64
Table: Top 20 Medicines Reimbursed By PHARMAC According To Prescription Numbers In The Year Ending June 2010
65
Recent Regulatory Developments
67
Competitive Landscape
70
Table: Licensed Medicine Manufacturing Sites
70
Company Profile
73
Douglas Pharmaceuticals
73
New Zealand Pharmaceuticals
76
Demographic Forecast
79
Table: New Zealand's Population By Age Group, 1990-2020 ('000)
80
Table: New Zealand's Population By Age Group, 1990-2020 (% of total)
81
Table: New Zealand's Key Population Ratios, 1990-2020
82
Table: New Zealand's Rural And Urban Population, 1990-2020
82
Glossary
83
Methodology
85
Pharmaceutical Expenditure Forecast Model
85
Healthcare Expenditure Forecast Model
85
Notes On Methodology
86

The New Zealand Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's New Zealand Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the New Zealand pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for New Zealand to test other views - a key input for successful budgeting and strategic business planning in the New Zealand pharmaceutical and healthcare market.
  • Target business opportunities and risks in the New Zealand pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in New Zealand.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc